Gao F, Wang J, Li C, Xie C, Su M, Zou C, Xie X, Zhao D. Risk-Related Genes and Associated Signaling Pathways of Gastrointestinal Stromal Tumors. IJGM 2022;Volume 15:3839-49. [DOI: 10.2147/ijgm.s357224][Reference Citation Analysis]
2
Chen T, Ni N, Yuan L, Xu L, Bahri N, Sun B, Wu Y, Ou WB. Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling. Front Pharmacol 2021;12:686874. [PMID: 34025442 DOI: 10.3389/fphar.2021.686874][Reference Citation Analysis]
3
Zhou L, Wang H, Liu H, Huang Z, Wang Z, Xiaojun Z, Mu X. The synergistic therapeutic effect of Imatinib and Protein Kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101886][Reference Citation Analysis]